Università Vita-Salute San Raffaele
🇮🇹Italy
Pooled Analysis Shows Improved OS Outcomes with Ibrutinib Plus Venetoclax in CLL Patients
A pooled analysis of the GLOW trial and CAPTIVATE-FD study reveals that first-line, fixed-duration treatment with ibrutinib plus venetoclax significantly improves overall survival (OS) outcomes in treatment-naive chronic lymphocytic leukemia (CLL) patients, with OS estimates comparable to an age-matched general European population.
© Copyright 2025. All Rights Reserved by MedPath